Book reviews
Proving New Drugs A Guide to Clinical Trials by Ben-Zion Taber MD pp xxi+182 $12 Los Altos, Calif.: Geron-X 1969 The weakest part of many new drug investigations is the clinical assessment. It is in the interests of both the medical profession and the pharmaceutical industry that the standard of clinical pharmacology and therapeutic trials should be raised. This book is a guide to the execution of clinical trials written from the standpoint of a medical director of a pharmaceutical company. There are chapters on the planning and design of clinical studies, the statistician's contribution and the choice of investigators. The text is interesting but its brevity leads to a somewhat superficial approach.
The book is directed towards the design of studies which comply with the requirements of the US Food and Drug Administration and this lessens its interest for the general reader. However, anyone who wants to know how to prepare and file an NDA or IND will receive guidance. The book is likely to appeal chiefly to members of the staff of pharmaceutical companies operating in the United States. The conference was reminded that the development of family planning had been in the hands of dedicated people; that medical and other professions had often unreasonably projected personal moral judgment. Thinking has changed rapidly and the Family Planning Act, 1967, has brought to fruition many of the dreams of the pioneers.
Contraception seemed a more desirable alternative to abortion, and in this the conference was not satisfied that we had reached the right degree of priority; in addition, there were still other important matters to decide before the pioneers' ideals were realized.
The points raised can be briefly summarized as follows: Family planning facilities ought to be available at all hospitals. Public opinion will demand such a service. Clinics could be used as-a basis for screening for female sexual disorders. Encouragement is needed for family planning for problem families and the lower social classes, who use contraceptives least. Doctors must take a greater interest since modern female contra-
